LKFT.US Lakefront Biotherapeutics NV
- Market cap
- USD 2.24B
- P/E
- 2.4x
- P/B
- 0.62x
- ROE
- 0.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LKFT.US undervalued?
Graham numberThe Graham number of Lakefront Biotherapeutics NV cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lakefront Biotherapeutics NV fundamental analysis
No fundamental analysis for Lakefront Biotherapeutics NV yet.
Lakefront Biotherapeutics NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product ca…
Full company profileLakefront Biotherapeutics NV financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lakefront Biotherapeutics NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 234M | 241M | 240M | 276M | 1.11B | 34.8M |
| Gross Profit | -86.1M | 241M | 240M | 241M | 1.08B | -22.6M |
| Operating Income | -172M | -131M | -88.3M | -188M | 501M | -197M |
| EBITDA | -163M | 3.87M | 51.0M | 43.3M | 359M | -89.3M |
| Net Income | -103M | -218M | 212M | 74.1M | 321M | 18.6M |
| EPS | -1.58 | -3.32 | 3.21 | 1.12 | 4.87 | 0.28 |
| Balance Sheet | ||||||
| Total Assets | - | 4.73B | 4.36B | 4.14B | 3.41B | 3.35B |
| Total Liabilities | - | 2.21B | 1.56B | 1.24B | 171M | 62.9M |
| Shareholders' Equity | - | 2.53B | 2.80B | 2.90B | 3.24B | 3.29B |
| Cash & Short-term Investments | - | 508M | 167M | 64.2M | 3.00B | 2.22B |
| Total Debt | - | - | - | - | 6.92M | 3.15M |
| Cash Flow | ||||||
| Operating Cash Flow | - | -501M | -406M | -320M | -257M | -200M |
| Capital Expenditure | - | 36.9M | 19.3M | 82.1M | 13.9M | 404K |
| Free Cash Flow | - | -537M | -425M | -402M | -271M | -200M |
| Ratios | ||||||
| ROE | - | -8.6% | 7.6% | 2.6% | 9.9% | 0.6% |
| ROA | - | -4.6% | 4.9% | 1.8% | 9.4% | 0.6% |
| Net Profit Margin | -44.0% | -90.4% | 88.3% | 26.9% | 28.9% | 53.4% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lakefront Biotherapeutics NV dividends
Lakefront Biotherapeutics NV has not paid dividends in the last 4 fiscal years.
Who owns Lakefront Biotherapeutics NV
- Insiders 26.43%
- Institutions 24.14%
- Public & others 49.43%
- Shares outstanding 65.9M
- Free float 462M
Top funds holding LKFT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 378K | 0.57% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 339K | 0.51% | -0.19% | Oct 2026 |
| Columbia VP Overseas Core 3 | 280K | 0.43% | -19.11% | Jun 2026 |
| ALPS Medical Breakthroughs ETF | 81.6K | 0.12% | 0.00% | Oct 2026 |
| Barometer International Equity A | 40.8K | 0.06% | 0.00% | Oct 2026 |
| Avantis International Equity ETF | 36.8K | 0.06% | 0.00% | Oct 2026 |
| Steward Values Enhanced International I | 33.3K | 0.05% | +8.77% | Sep 2026 |
| ActivePassive International Equity ETF | 15.8K | 0.02% | 0.00% | Oct 2026 |
| ERSTE STOCK BIOTEC EUR R01 A | 14.0K | 0.02% | 0.00% | Aug 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 12.6K | 0.02% | +0.20% | Oct 2026 |
| Avantis International Small Cp Eq ETF | 7.61K | 0.01% | 0.00% | Oct 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 4.13K | 0.01% | +1.93% | Oct 2026 |
| Acadian Global Dev Enh EqC4i0.2000USDLU3 | 3.73K | 0.01% | 0.00% | Jun 2026 |
| Prisma Cube | 3.00K | 0.00% | 0.00% | Jun 2026 |
| VanEck Genomics and Healthcare Inn ETF | 2.61K | 0.00% | 0.00% | Oct 2026 |
| Avantis® International Equity Instl | 2.48K | 0.00% | 0.00% | Sep 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 2.39K | 0.00% | +1.57% | Jun 2026 |
| Invesco Nasdaq Biotechnology ETF | 1.19K | 0.00% | 0.00% | Oct 2026 |
| ProShares Ultra Nasdaq Biotechnology | 594.00 | 0.00% | 0.00% | Oct 2026 |
| Avantis Global Equity ETF USD Acc ETF | 569.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding LKFT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 3.79M | 5.75% | 0.00% | Jun 2026 |
| Madison Avenue Partners, LP | 3.45M | 5.23% | +39.86% | Jun 2026 |
| Prosight Management, LP | 2.00M | 3.03% | -2.20% | Sep 2026 |
| EcoR1 Capital, LLC | 1.67M | 2.53% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 1.27M | 1.93% | -10.70% | Jun 2026 |
| Renaissance Technologies Corp | 425K | 0.64% | +4.14% | Sep 2026 |
| BlackRock Inc | 338K | 0.51% | +8.35% | Jun 2026 |
| Point72 Asset Management, L.P. | 270K | 0.41% | -18.76% | Jun 2026 |
| D. E. Shaw & Co LP | 198K | 0.30% | -8.29% | Jun 2026 |
| Millennium Management LLC | 181K | 0.27% | +67.81% | Jun 2026 |
| UBS Group AG | 168K | 0.26% | -4.07% | Jun 2026 |
| Susquehanna International Group, LLP | 152K | 0.23% | +1,034.58% | Jun 2026 |
| Dafna Capital Management LLC | 130K | 0.20% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 88.3K | 0.13% | -29.00% | Jun 2026 |
| Two Sigma Investments LLC | 81.7K | 0.12% | +216.12% | Jun 2026 |
| NORGES BANK | 76.9K | 0.12% | -14.58% | Jun 2026 |
| ALPS Advisors Inc | 65.5K | 0.10% | +22.11% | Jun 2026 |
| The Goldman Sachs Group Inc | 56.6K | 0.09% | +24.71% | Jun 2026 |
| American Century Companies Inc | 41.4K | 0.06% | +1.38% | Sep 2026 |
| Barometer Capital Management Inc | 40.8K | 0.06% | +7.09% | Jun 2026 |
Lakefront Biotherapeutics NV company profile
- Company name
- Lakefront Biotherapeutics NV
- Ticker
- LKFT.US
- Exchange
- USA Stocks
- Listed since
- May 14, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 196
- Fiscal year end
- December
- Address
- SchaliEnhoevedreef 20 T, Mechelen, Belgium, 2800
- Phone
- 32 1 534 29 00
- Website
- lakefrontbio.com
About Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Lakefront Biotherapeutics NV management
10- Mr. Henry O. GosebruchCEO & Executive Director · born 1973
- Mr. Aaron L. CoxChief Financial Officer · born 1984
- Ms. Christina Carlson J.D.Chief Operating Officer
- Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.Head of Investor Relations
- Mr. Fred W. Blakeslee IIExecutive VP & General Counsel
- Marieke VermeerschHead of Corporate Communication
- Ms. Tania PhilippChief People Officer · born 1972
- Ms. Ellen Van Der AarHead of Development
- Dr. Jeevan ShettyHead of Clinical Development Oncology
- Ruiz AstigarragaHead of Manufacturing Cell Therapy